Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:38 PM
Ignite Modification Date: 2025-12-25 @ 1:10 PM
NCT ID: NCT00624559
Description: None
Frequency Threshold: 0
Time Frame: None
Study: NCT00624559
Study Brief: The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Celebrex, High Sodium Each subject completes a normal sodium diet (3 days), a high salt diet (7 days), and a low salt diet (7 days) while taking either a placebo or celebrex (each trial is 17 days long). Each subject completes 2 full 17 day trials (one month 'washout' between each trial); one time taking the placebo and one taking celebrex (randomized). None None 0 3 0 3 View
Celebrex, Low Sodium 100 mg Celebrex, twice per day for 7 days on low sodium diet None None 0 3 0 3 View
Placebo, Low Sodium Placebo pill taken twice per day over the course of the diet None None 0 3 0 3 View
Placebo, High Sodium Placebo pill taken twice per day over the course of the diet None None 0 3 0 3 View
Serious Events(If Any):
Other Events(If Any):